Please assess the completion status of the following clinical trial:

Trial Title: Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Phase 1:~  * Age \>18 years~ * Calculated creatinine clearance \>70 mL/min/1.73 m2 (measured within 3 months)~ * Written informed consent~Phase 2:~* Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG)~* Ability and willingness to provide informed consent~* Willing to receive protocol-specified lumbar punctures~Exclusion Criteria:~* Phase 1:~  * Symptomatic Current illness~ * Known significant, untreated health problem~ * Inability to take enteral medicine~ * Pregnant or breast feeding~ * Receiving amphotericin B therapy in past 90 days~* Phase 2:~  * Presenting Glasgow Coma Scale (GCS) \< 15~ * Received 3 or more doses of IV amphotericin therapy within last 30 days~ * Inability to take enteral (oral or nasogastric) medicine~ * Cannot or unlikely to attend regular clinic visits~ * Pregnancy or breastfeeding~ * Receiving chemotherapy or corticosteroids~ * Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS)~ * Recent initiation of HIV therapy or ART class switch (within 2 weeks)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1a single ascending dose study (Type: EXPERIMENTAL): Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.
- Phase 1b multiple day dosing (Type: EXPERIMENTAL): 9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.
- Phase 2 safety and tolerability (Type: EXPERIMENTAL): Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.

Based on this trial design, predict the completion outcome and termination type (if applicable).